An expert in hematology/oncology, Dr Yi-Bin Chen, provides insight on chronic GvHD, with a focus on early detection of disease and therapeutic options for the management of steroid-refractory chronic GvHD.

Alina Markova, MD, highlights the safety and tolerability of topical ruxolitinib INCB018424 phosphate 1.5% cream for patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Using skin-sparing mastectomy and immediate deep inferior epigastric perforator flap reconstruction following preoperative radiotherapy was safe and feasible in patients with primary breast cancer.

Three year follow-up findings from a post hoc analysis of the phase 3 ARAMIS trial indicated that darolutamide maintained a survival benefit regardless of prior local therapy for patients with nonmetastatic castration-resistant prostate cancer.

In the phase 2 MOUNTAINEER trial, patients with previously treated HER2-positive metastatic colorectal cancer who were treated with tucatinib plus trastuzumab were shown to have an improved objective response rate.

Lori Wirth, MD, provides an overview of differentiated thyroid cancer including treatment options that are currently available, as well as sharing insights on emerging therapies.

Experts review a second patient case wherein transplant-ineligible newly diagnosed multiple myeloma was treated with the daratumumab, lenalidomide and dexamethasone regimen and how updated data from the MAIA trial can be incorporated into clinical practice.

Experts discuss efficacy data from the ELEVATE-RR trial on the Bruton tyrosine kinase inhibitors acalabrutinib vs ibrutinib.

Considerations for assessing eligibility of patients for transplantation for NDMM and how maintenance therapy may be initiated in the post-transplant setting.

Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.